Could treatment modification based on early response assessment improve results in DLBCL?
Hari S. Raman(Dana-Farber Cancer Institute), Jennifer L. Crombie(Dana-Farber Cancer Institute)
Cited by 0
Related Papers
PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation
|Blood|2019|187
Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy
|Blood|2024|132
The treatment of Burkitt lymphoma in adults
|Blood|2020|105
Epstein Barr Virus Associated B-Cell Lymphomas and Iatrogenic Lymphoproliferative Disorders
|Frontiers in Oncology|2019|104